Residential REIT's

There are currently over 50 U.S. Small-Cap issues whether categorized as, growth, value or blend. This is overwhelming for most investors. Using our long experience as an ETF publication, we try to help select those ETFs that matter even if where they might be repetitive. The result is a more...

MAA (NYSE: MAA) announced today that it has completed the acquisition of Allure in Buckhead Village, a 230-unit mid-rise multi-family apartment community located in Atlanta, Georgia. Allure in Buckhead Village was developed in 2002 by Trammell Crow Residential and is located in the desirable...

According to a research report published this morning, Jefferies has increased Mid America Apartments' (NYSE: MAA) PT from $74 to $77. In the report, Mid America Apartments commented, "SS opex growth of +4.5% at MAA in 1Q12 was well ahead of its peers (EQR @ +1.8%, AVB @ -1.1%, ESS @ -0.7%, AEC...

The following are the M&A deals, rumors and chatter circulating on Wall Street for Tuesday April 3, 2012: Royal Bank of Canada to Acquire Full Ownership of RBC Dexia Investor Services The Deal: Royal Bank of Canada (NYSE: RY) announced Tuesday that it has entered into a definitive agreement...

MAA (NYSE: MAA) announced today that it has completed the acquisition of Adalay Bay, a 240-unit apartment community located in Chesapeake, Virginia. Adalay Bay was developed in 2002 and is located in the very desirable Hampton Roads area of Chesapeake which is part of the Norfolk-Virginia Beach-...

Pre-open movers US stock futures are higher this morning, as investors are awaiting pending home sales report. Futures for the Dow Jones Industrial Average gained 47 points to 13,079.00 and S&P 500 index futures rose 4.90 points to 1,399.00. Nasdaq 100 futures gained 13.75 points to 2,742.50....

Raptor Pharmaceutical Corp. (Nasdaq: RPTP), announced that the European Medicines Agency has determined that Raptor's Marketing Authorization Application (MAA) for its investigational drug candidate, RP103 for the potential treatment of nephropathic cystinosis, submitted earlier this month, is...

Endocyte, Inc. (Nasdaq: ECYT) today announced that, per discussions with EU health authorities, the Company will submit EU conditional marketing authorization applications (MAA) for EC145 and EC20 for treatment of patients with folate-receptor positive platinum resistant ovarian cancer. The...

MAA (NYSE: MAA) today announced the closing of a $150 million unsecured term loan agreement. The loan has a five-year term and a variable interest rate of LIBOR plus a spread of 1.40% to 2.15%, depending on the company's leverage levels. At the time MAA obtains an additional investment grade rating...

MAA (NYSE: MAA) today announced that it is offering 1,700,000 shares of common stock in an underwritten public offering. UBS Investment Bank and Jefferies & Company, Inc. will act as joint bookrunning managers for the offering. MAA has also granted the underwriters a 30-day option to purchase...

Genzyme, a Sanofi company (NYSE: SNY), announced today the European Medicines Agency (EMA) has accepted the filing of the marketing authorization application (MAA) for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis (MS). Acceptance of the MAA starts the EMA...

Keefe, Bruyette & Woods reiterated its Mid-America Apartment Communities (NYSE: MAA) Outperform rating in a research report published today. Keefe, Bruyette & Woods has a $69 price target on the company. In the report, Keefe, Bruyette & Woods states, "MAA stacks up favorably versus...

In a research report published today, Jefferies gave bits of insight into the future of several different companies. Jefferies downgraded SL Green Realty Corp. (NYSE: SLG) from Buy to Hold, and upgraded Mid-America Apartment Companies Inc. (NYSE: MAA) from Hold to Buy. In the report, for example...

Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that it has earned a $5 million milestone payment from Bayer Healthcare for the achievement of all efficacy and safety objectives in the TR701-112 Phase 3 pivotal study which tested the oral dosage form of tedizolid phosphate versus the...

Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that tedizolid phosphate met the primary objective of non-inferiority for the efficacy outcome of early clinical response versus the comparator linezolid (Zyvox®) in patients with acute bacterial skin and skin structure infections (ABSSSI)....